| Cost-effectiveness analysis of tisagenlecleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma in the United States CZ Qi, V Bollu, H Yang, A Dalal, S Zhang, J Zhang Clinical Therapeutics 43 (8), 1300-1319. e8, 2021 | 23 | 2021 |
| Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States D Muston, R Hettle, M Monberg, KK McLaurin, W Gao, E Swallow, ... Gynecologic Oncology 159 (2), 491-497, 2020 | 19 | 2020 |
| Treatment patterns and outcomes in resected early-stage non-small cell lung cancer: an analysis of the SEER-Medicare data H West, X Hu, S Zhang, Y Song, D Chirovsky, C Gao, A Lerner, A Jiang, ... Clinical lung cancer 24 (3), 260-268, 2023 | 17 | 2023 |
| Strategic interaction among governments in the provision of a global public good MK Kyle, DB Ridley, S Zhang Journal of Public Economics 156, 185-199, 2017 | 17 | 2017 |
| Systematic literature review of clinical and economic evidence for spinal muscular atrophy M Yang, H Awano, S Tanaka, W Toro, S Zhang, O Dabbous, A Igarashi Advances in therapy 39 (5), 1915-1958, 2022 | 10 | 2022 |
| Real-world adherence to tetrabenazine or deutetrabenazine among patients with Huntington’s disease: a retrospective database analysis DO Claassen, R Ayyagari, V Garcia-Horton, S Zhang, J Alexander, S Leo Neurology and Therapy, 1-14, 2022 | 7 | 2022 |
| Disease-free survival as a predictor of overall survival in localized renal cell carcinoma (RCC) following first nephrectomy. NB Haas, Y Song, J Willemann Rogerio, S Zhang, O Adejoro, C Carley, ... Journal of Clinical Oncology 39 (15_suppl), 4581-4581, 2021 | 6 | 2021 |
| A critical appraisal and recommendations for cost-effectiveness studies of poly (ADP-ribose) polymerase inhibitors in advanced ovarian cancer W Gao, D Muston, M Monberg, K McLaurin, R Hettle, E Szamreta, ... Pharmacoeconomics 38, 1201-1218, 2020 | 6 | 2020 |
| Disease‐free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: a retrospective analysis of surveillance, epidemiology … NB Haas, Y Song, J Willemann Rogerio, S Zhang, C Carley, JJ Zhu, ... International Journal of Urology 30 (3), 272-279, 2023 | 5 | 2023 |
| Clinical and economic burdens of recurrence following nephrectomy for intermediate high-or high-risk renal cell carcinoma: A retrospective analysis of Surveillance … M Sundaram, Y Song, JW Rogerio, S Zhang, R Bhattacharya, O Adejoro, ... Journal of Managed Care & Specialty Pharmacy 28 (10), 1149-1160, 2022 | 4 | 2022 |
| Event-free survival as a predictor of overall survival and recurrence burden of patients with non–small cell lung cancer receiving neoadjuvant therapy J Donington, X Hu, S Zhang, Y Song, A Arunachalam, D Chirovsky, C Gao, ... The Journal of thoracic and cardiovascular surgery, 2023 | 3 | 2023 |
| Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non–small cell lung cancer H West, X Hu, S Zhang, Y Song, D Chirovsky, C Gao, A Lerner, A Jiang, ... Journal of managed care & specialty pharmacy 29 (7), 749-757, 2023 | 2 | 2023 |
| Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia DO Claassen, R Ayyagari, V García-Horton, S Zhang, S Leo Mental Health Clinician 13 (5), 207-216, 2023 | 1 | 2023 |
| Disease management costs for patients with intermediate-high or high-risk renal cell carcinoma (RCC) following nephrectomy Y Lai, Y Song, S Zhang, R Bhattacharya, C Carley, A Bensimon VALUE IN HEALTH 25 (12), S128-S128, 2022 | 1 | 2022 |
| Variation in recurrence rate and overall survival (OS) outcomes by disease stage and incremental impact of time to recurrence on OS in localized renal cell carcinoma (RCC). NB Haas, R Bhattacharya, Y Song, J Rogerio, S Zhang, C Carley, ... Journal of Clinical Oncology 40 (16_suppl), 4543-4543, 2022 | 1 | 2022 |
| Cost-effectiveness analysis of olaparib as a maintenance monotherapy for patients with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation: A United States payer … DRG Muston, MJ Monberg, K McLaurin, A Sackeyfio, R Hettle, ... Gynecologic Oncology 159, 140-141, 2020 | 1 | 2020 |
| EE407 Treatment Patterns and Healthcare Resource Utilization in Ruxolitinib-Treated Patients with Myelofibrosis with and without Anemia: A Real-World Analysis T Liu, M Fillbrunn, J Chen, G Sajeev, S Zhang, J Signorovitch Value in Health 27 (6), S132, 2024 | | 2024 |
| Real-world treatment patterns and overall survival (OS) in locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC) in the US D Zheng, S Zhang, B Bidadi, N Lerman, Y Song, R Song, J Li, A Zhu, ... Journal of Clinical Oncology 42 (16_suppl), e23275-e23275, 2024 | | 2024 |
| Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non–Small-Cell Lung Cancer J Donington, X Hu, S Zhang, Y Song, A Arunachalam, D Chirovsky, C Gao, ... Clinical Lung Cancer, 2024 | | 2024 |
| P1. 25-06 Real-world Primary Treatment Patterns in Stages I-III Non-Small Cell Lung Cancer JS Donington, X Hu, S Zhang, C Gao, A Arunachalam, D Chirovsky, ... Journal of Thoracic Oncology 18 (11), S270-S271, 2023 | | 2023 |
